Biomedicines (Jul 2022)

Pain and Opioid-Induced Gut Microbial Dysbiosis

  • Karen R. Thomas,
  • Jacob Watt,
  • Chuen Mong J. Wu,
  • Adejoke Akinrinoye,
  • Sairah Amjad,
  • Lucy Colvin,
  • Rachel Cowe,
  • Sylvia H. Duncan,
  • Wendy R. Russell,
  • Patrice Forget

DOI
https://doi.org/10.3390/biomedicines10081815
Journal volume & issue
Vol. 10, no. 8
p. 1815

Abstract

Read online

Opioid-induced dysbiosis (OID) is a specific condition describing the consequences of opioid use on the bacterial composition of the gut. Opioids have been shown to affect the epithelial barrier in the gut and modulate inflammatory pathways, possibly mediating opioid tolerance or opioid-induced hyperalgesia; in combination, these allow the invasion and proliferation of non-native bacterial colonies. There is also evidence that the gut-brain axis is linked to the emotional and cognitive aspects of the brain with intestinal function, which can be a factor that affects mental health. For example, Mycobacterium, Escherichia coli and Clostridium difficile are linked to Irritable Bowel Disease; Lactobacillaceae and Enterococcacae have associations with Parkinson’s disease, and Alistipes has increased prevalence in depression. However, changes to the gut microbiome can be therapeutically influenced with treatments such as faecal microbiota transplantation, targeted antibiotic therapy and probiotics. There is also evidence of emerging therapies to combat OID. This review has collated evidence that shows that there are correlations between OID and depression, Parkinson’s Disease, infection, and more. Specifically, in pain management, targeting OID deserves specific investigations.

Keywords